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Abstract
Background: Passively acquired maternal antibodies are necessary to protect infants against circulating measles
virus until they reach the eligible age of vaccination. Likewise, high levels of population immunity must be
achieved and maintained to reduce measles virus transmission. This study was undertaken to (1) assess the
presence of maternally acquired measles-specific IgG antibodies among infants less than 9 months of age in
Bangui, Central African Republic and (2) determine the immune status of vaccination-age children and the
concordance with reported vaccination status. A secondary objective was to describe the presence of rubella-
specific IgG antibody in the study population.
Methods: Vaccination history and blood samples were collected from 395 children using blotting paper. Samples
were analyzed for the presence of measles-specific IgG antibodies using commercial ELISA kits.
Results: Measles-specific IgG antibodies were detected in 51.3% of vaccinated children and 27.6% of non-
vaccinated children. Maternally derived measles IgG antibodies were present in only 14.8% of infants aged 0-3
months and were absent in all infants aged 4-8 months. The presence of IgG-specific measles antibodies varied
among children of vaccination age, from 57.3% for children aged 9 months to 5 years, to 50.6% for children aged
6-9 years and 45.6% for chidren aged 10 years and above. The overall prevalence of rubella-specific IgG was 55.4%,
with a high prevalence (87.4%) among children over 10 years of age.
Conclusion: The findings suggest that despite efforts to accelerate measles control by giving a second dose of
measles vaccine, a large number of children remain susceptible to measles virus. Further research is required to
determine the geographic extent of immunity gaps and the factors that influence immunity to measles virus in the
Central African Republic.
Background
Since 2000, significant progress has been made to
reduce the global burden of measles. Nowhere has this
achievement been more pronounced than in Africa.
Through effective implementation of WHO- and UNI-
CEF-recommended control strategies, the estimated
measles-related mortality decreased by 90% in the Afri-
can Region between 2000 and 2008. In particular, a sec-
ond dose of measles-containing vaccine (MCV) given
during supplemental immunization activities played a
vital role in raising population immunity levels, although
routine vaccination coverage remains low and health
systems weak.
In spite of the gains, measles morbidity and mortality
continue to be an important public health concern for
Africa’s impoverished children, who have poorer access
to vaccination and curative services. Moreover, the
recent resurgence of measles outbreaks, cases and
deaths is a necessary reminder of how short-lived
immunity gains and progress can be [1]. All countries in
the WHO African Region now offer a second dose of
MCV, typically by organizing periodic supplemental
immunization activities. Where routine immunization
coverage remains low and systems are weak, supplemen-
tal activities have been shown to be an effective
mechanism for raising population immunity levels.
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country in central equatorial Africa that borders five
other countries: Chad to the north, Sudan to the east,
t h eD e m o c r a t i cR e p u b l i co ft h eC o n g oa n dt h eC o n g o
to the south, and Cameroon to the west. The esti-
mated total population in 2008 was 4.4 million,
approximately 20% of whom live in the capital, Bangui.
CAR is one of the poorest countries in the region and
the world, with a human development index of 0.369,
ranking 179 out of 182 countries [2]. The estimated
mortality rate of children under 5 was 172 per 1000
live births in 2008 [3]
As in the rest of the African Region, measles control
in CAR improved markedly during the past decade. In
2000, there were 3207 reported measles cases, and the
measles vaccination coverage was 36% [WHO-UNICEF
Best Estimates]. Between 2000 and 2005, routine
measles vaccination coverage made steady gains, and it
was estimated to be 62% in 2005. In late October 2005,
the country initiated second-dose measles catch-up vac-
cination campaigns as part of the Measles Initiative’s
efforts to reduce measles-related mortality (CAR Minis-
try of Health data). The nationwide campaign was con-
ducted in two phases (November 2005 and January-
February 2006) and targeted all children aged between 6
months and 14 years. Overall, 1.7 million children were
vaccinated, and administrative coverage was estimated
to be greater than 90%.
Measles surveillance with laboratory-based serology to
confirm outbreaks was launched in 2003. Previously,
cases were reported on the basis of a clinical case defini-
tion of fever plus rash and either cough, conjunctivitis
or coryza. As recommended in the WHO Regional
Office for Africa’s standard diagnostic protocol, sus-
pected cases that meet the definition of a clinical case of
measles and test negative for measles are analyzed dif-
ferentially for the presence of rubella IgM antibodies.
This secondary information provides important epide-
miologic data on rubella virus transmission, which pre-
viously was unrecognized and poorly understood. The
Institut Pasteur de Bangui is the National Measles Refer-
ence Laboratory for the Ministry of Health. After the
measles catch-up campaigns of 2005-2006, case-based
laboratory supported measles surveillance was rolled out
in earnest to the entire country.
A more direct and complementary manner of assessing
vaccination activities and the level of community protec-
tion against measles is to evaluate the immunoglobulin
response of a population to a given vaccine antigen. In
addition, by including pre-vaccine eligible infants (<9
months of age), this study seeks to improve understand-
ing of the duration of passively acquired maternal protec-
tion to measles virus in the CAR context.
Thus, the primary objectives of this study were to
assess the presence of maternally acquired measles-spe-
cific antibodies in infants not yet eligible for MCV in
routine services (children <9 months of age) in the capi-
tal city, Bangui and to determine the immune status of
vaccination-age children and the association with
reported vaccination status. A secondary objective of
this investigation was to describe the presence of
rubella-specific IgG antibody in the study population.
Methods
Study design and population
This study was conducted in Bangui, the capital of CAR,
between June and December 2008. The study partici-
pants were drawn from a list of 11 pre-determined
clinics, hospitals and primary and secondary schools.
Healthy children aged 1 month to 15 years were eligible.
Children with recently reported acute infectious or
chronic disease (i.e. cardiopathy, bronchitis or renal dis-
ease), malnutrition, or sickle-cell disease or with HIV
infection were excluded from the study. Written
informed consent for children’s participation in the
study was obtained from parents and legal guardians
before the start of the study. This study was ethically
approved by the local review board of the University of
Bangui Medical Research Committee.
A trained investigator used a standardized question-
naire to collect information from parents or legal guar-
dians about age, sex, vaccination status and date of the
last dose of vaccine received. Verbal vaccination history
was cross-checked with a child’s immunization card
when available.
A non-probability quota sample was used to sample
study participants. The number of participants was
determined after assuming a confidence interval of 5%
and desired 1-ß (Power) of ≥80% when comparing pro-
portions between age groups. Thus, the minimum sam-
ple size for the study was 384 children.
Sample testing
Blood samples were collected on filter paper from a fin-
ger or heel (children <6 months) prick and transported
to the Institut Pasteur de Bangui, where they were ana-
lyzed for measles and rubella. Measles- and rubella-spe-
cific IgG antibodies were detected with enzyme-linked
immunosorbent assays (ELISAs), Platelia™ Measles IgG
(Bio-Rad, Ref 72686) and Platelia
® Rubella IgG TMB
(Bio-Rad, Ref. 72912). The presence of IgG antibodies
was determined by comparing the optical density (OD)
to a standard range. For measles, a qualitative result was
obtained by comparing the patient OD to the cut-off
OD (index). Results were interpreted as negative if the
index was <0.8, doubtful if it was between 0.8 and 1.2
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dies to measles as per the kit instructions.
For rubella, the OD was converted into international
units per milliliter by plotting a standard curve for each
assay. Results were interpreted as negative (titer ≤10 UI/
ml), doubtful (titer 10-15 UI/ml) or positive (titer ≥15
UI/ml) according to the kit instructions. For both
measles and rubella, serum samples with doubtful
results were automatically retested. If the same result
was obtained, the case was classified as negative for the
purposes of this study.
Data management
Data were entered, verified for consistency and analyzed
with EpiInfo software version 3.5.1 (CDC, Atlanta, Geor-
gia, USA). Results are expressed as numbers and percen-
tages. Chi-square tests were performed to assess
differences between groups. A p value of < 0.05 was
considered statistically significant.
Results
Study population characteristics and vaccination status
The study population consisted of 395 children
recruited from the outpatient care wards of two health
centers (42.8%) and seven kindergartens, primary and
secondary schools (57.2%). The breakdown of study sub-
jects on the basis of age is shown in Table 1. Slightly
more girls than boys (53% vs. 47% or sex-ratio M/F =
0.9) participated in the study. The youngest age group,
infants aged 0-8 months, was categorized as unvacci-
nated, as routine immunization with measles vaccine in
the national guidelines is performed only for infants
f r o m9m o n t h so fa g e .T h em e a na n dm e d i a na g e so f
the study subjects were 64.7 and 55 months, respec-
tively. This did not differ by sex.
The reported vaccination coverage with routine services
was 39.5% (156/395). When only eligible children were con-
sidered (infants aged ≥9 months), the reported routine cov-
erage increased to 58.2% (152/261). Coverage increased
further to 83.1% when allowing for either routine or the
catch-up campaign (217/261), as per verbal reports from
care givers. Nearly all infants under 1 year of age had a rou-
tine immunization card (147/148). As expected, possession
of an immunization card decreased with increasing age, and
only 4.9% (5/103) of the children aged ≥10 years had an
immunization card. Details of the vaccination status of
study subjects, by age, are presented in Table 1.
Measles-specific antibody response among infants 0-8
months of age
Of the 133 infants aged 0-8 months enrolled in the
study, 13 (9.8%) had measles-specific IgG antibody. IgG
antibodies were found only in neonates and infants aged
1-2 months. No measles-specific IgG antibody was
detected among infants aged 3-8 months. Although
three infants in this age group (one aged 6 months and
two aged 8 months) had documented proof of measles
vaccination, none of these infants had detectable
measles-specific IgG antibodies (Figure 1).
9 months of age",1,0,1,0,0pc,0pc,0pc,0pc>Measles-specific
antibody response among children >9 months of age
The presence of measles-specific IgG antibody increased
with age to 57.3% (43/75) for children aged 9 months to
5 years. For older children, however, there was a general
decrease in IgG presence by age group to 50.6% (42/83)
for those aged 6-9 years and 45.6% (47/103) for chilren
aged ≥10 years. Among children aged 9 months and
older, vaccinated children were more likely to have
detectable measles-specific IgG antibodies than unvacci-
nated children (53.5% vs. 36.4%; chi-square = 4.28; p =
0.04). See Figure 2.
Rubella-specific antibodies
More than the half of all studied children (55.4%; 219/
395) had rubella-specific antibodies. Presence of rubella-
specific IgG antibodies increased with increasing age of
study subjects with protective antibody in 38% of chil-
dren 1-4 years of age, 71% of children 5-9 years of age,
and 87% of children 10 years of age and older. Of 148
children <12 months of age, 31.8% had rubella-specific
IgG antibodies but none of the children 7-11 months of
age (0/23) had detectable antibody. Presence of rubella-
specific IgG antibodies was distributed equally between
males and females (male: 44.1%, female: 55.9%; p = 0.9).
See Figure 3.
Table 1 Vaccination status of study subjects during routine immunization and SIA by age
Age group Vaccination in RI* Vaccination during SIA** Possession of vaccination card Total
n% n % n %
0-8 months 3 2.3% 0 0.0% 133 100.0% 133
9-59 months 61 81.3% 42 56.0% 37 49.3% 75
6 - 9 years 58 69.9% 56 67.5% 14 16.9% 83
≥10 years 33 32.0% 52 50.5% 5 4.9% 103
Total 155 39.3% 150 38.1% 189 48.0% 394
*RI = routine immunization; **SIA = supplementary immunization activities
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Figure 1 Presence of measles-specific IgG antibody, infants aged 0-8 months.
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Figure 2 Presence of measles specific IgG antibody and reported vaccination by age group.
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This study documents for the first time the seropreva-
lence of measles-specific IgG antibodies among children
in the CAR. The results suggest that population immu-
nity to measles vaccine is well below the threshold
(>90%) necessary to interrupt measles transmission. Pro-
tective antibody levels were more prevalent among chil-
dren eligible for vaccination and among those reported
to have been vaccinated; however, only 50% of vaccina-
tion-age children had protective antibodies. Passively
derived maternal protection to measles vaccine among
infants aged 0-8 months was also low (9.8%) and unde-
tectable past 3 months of age, leaving this vulnerable
population susceptible to wild virus circulation. The rea-
sons for low maternal transfer of measles-specific anti-
body and the lower-than-expected population protection
are not clear.
Low, waning maternal antibody protection, which
results in an increased period of susceptibility to natural
infection before vaccination eligibility, typically at 9
months of age, has been documented in various devel-
oping countries [4-9]. In a recent study in Bangladesh,
only 50% of infants aged 1-3 months had protective
antibodies and infants aged >3-9 months had no protec-
tion at all, similar to our findings [8]. Two studies con-
ducted in the past 10 years in sub-Saharan Africa
reported similar results. In Nigeria, Hartter et al. found
that only 17% of 4-month-old Nigerian infants were still
protected against measles [7], while in Mali, only 30% of
2-month-old infants had protective antibody titers [9].
Reporting results from Libreville, Gabon, more than 20
years ago, Grendel et al. found that 90% of children con-
sulting outpatient services were seronegative by 4
months of age [5]. During the same period, Dabis et al.
found rapid rates of passive maternal antibody loss,
from 96% at 2 months of age to less than 10% at 7-8
months of age in Brazzaville, Congo [4].
This body of research presents the accumulated
descriptive epidemiological evidence on this topic.
Unfortunately, there remains a dearth of analytic
research in Africa to determine the role and relative
importance of specific covariates associated with this
phenomenon. Furthermore, the epidemiologic context of
measles transmission has changed dramatically in the
past decade [10]. Accelerated measles control activities,
including improved routine immunization coverage, the
provision of a second dose of measles vaccine at supple-
mentary vaccination activities and case-based surveil-
lance with laboratory confirmation, have reduced
measles-associated morbidity and mortality to record
lows. Bolstered by these achievements, the African
Region is poised to adopt an elimination goal. Our
r e s u l t sa r ei m p o r t a n t ,b e c a u s et h e yp r o v i d ear a r e
glimpse into the serological profile of measles protection
in Africa after concerted, targeted efforts to raise popu-
lation immunity and reduce morbidity and mortality.
Factors known to affect the placental transfer of anti-
bodies, such as HIV and malaria infection, may be
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Figure 3 Natural rubella IgG responses by age group.
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Page 5 of 7associated with our study results [11]. CAR has an esti-
mated HIV seroprevalence rate of 6.2%, one the highest
in central Africa [12]. Attempts were made to ascertain
the HIV status of potential study subjects; however, ser-
ological screening was not undertaken. Falciparum
malaria transmission is haloendemic in much of the
country, including the capital Bangui, the site of the
study. Maternal histories of malaria episodes were not
collected.
UNICEF estimates that 38% of the country’sc h i l d r e n
suffer from global chronic malnutrition and 10% suffer
from global acute malnutrition [13]. While the effect of
malnutrition on maternal transfer of passive antibody
immunity is poorly understood, the scope and severity
of the problem indicate that it cannot be ignored. The
source of maternal immunity, wild virus versus vaccine-
derived, may also affect the amount of maternal anti-
body transferred transplacentally, with vaccinated
mothers passing on less immunity to their newborn
infants. Although routine vaccination rates increased
from 35% in 2003 to 62% in 2006, before this, routine
vaccination with measles antigen remained consistently
below 50%. For this reason, it is believed that the major-
ity of maternal immunity is likely derived from exposure
to circulating wild virus.
Our study also suggests lower-than-expected levels of
measles-specific IgG in the vaccination-eligible population,
and even a possible waning of serological immunity
among children aged ≥10 years. This is another result that
deserves further investigation. Reduced vaccine effective-
ness, due to compromised vaccine or host characteristics
that negatively affect seroconversion as well as reduced
exposure to circulating measles virus may all play a role.
This study has some potential limitations. The pre-
sence of protective antibodies may have been misclassi-
fied because of the diagnostic test used. The selection of
study subjects may also have biased our results.
Although children with recent episodes of acute illness
were ineligible for the study, some were nonetheless
recruited from outpatient clinic services. In addition, the
quota convenience sampling method used does not
allow results to be extrapolated to the wider population.
Determining the vaccination status of children and the
reliability of reports is always problematic in the absence
of the gold standard vaccination card. Thus, the vaccina-
tion status of study subjects may have been overesti-
mated. Lack of verification of the vaccination status of
the mothers is another weakness of this study.
National immunization programs must determine the
optimal age for the first dose of MCV1 by weighing the
risk for primary vaccine failure at younger ages against the
risk for measles virus infection before vaccination. This
study describes the wide window of vulnerability, between
the disappearance of passively acquired maternal antibody
and the eligible age of vaccination. The premature loss of
maternal antibodies, which, if present, would inhibit vacci-
nation seroconversion, opens the door to discussions of
the optimal age for vaccination in developing countries.
Conclusion
T h ep r e v a l e n c eo fm e a s l e sI g G - s p e c i f i ca n t i b o d i e so f
study children in Bangui is low, indicating that a large
number of children may not be protected against
measles. The rapid loss of maternal protective antibodies
opens a wide period of vulnerability of infants and sug-
gests that the first dose of measles vaccine could be
administered at an earlier age. Vaccine effectiveness stu-
dies in younger age groups with an additional dose admi-
nistered at or close to 12 months, when vaccine
effectiveness is higher, could be tested. In the meantime,
the quality of vaccination activities (routine and supple-
mentary immunization campaigns) must be improved,
and population awareness of their importance must be
increased. Monitoring routine immunization coverage to
assess administrative coverage levels, which are habitually
unreliable, and robust methods to monitor and evaluate
supplementary immunization activities are needed. Com-
plementary sero-immunity studies to detail the dynamics
of measles and rubella IgG antibody responses in other
areas of the CAR should be conducted to better under-
stand the window of vulnerability of infants and the
immunity profile of old age groups throughout the coun-
try. In addition, rubella control and congential rubella
syndrome prevention (CRS) through the use of rubella
containing vaccine should be considered as per WHO
regional and global guidelines. Finally, as the routine
immunization system continues to improve and higher
coverage is achieved, the introduction of a second dose
of measles containing vaccine into the routine immuniza-
tion schedule should be considered.
Acknowledgements
We are grateful to all the children, parents, health centers, guardians and
school staff who participated in this study. We thank Sonia-Marilou
Pagonendji and Josiane Leal for valuable technical inputs. We also thank Dr
Mirdad Kazanji and Dr Elisabeth Heseltine for critical reading of the
manuscript. This work was funded by the World Health Organization.
Author details
1Institut Pasteur de Bangui, Réseau International des Instituts Pasteur, BP 923,
Bangui, Central African Republic.
2World Health Organization, Libreville,
Gabon.
3World Health Organization, New Delhi, India.
4World Health
Organization, Bangui, Central African Republic.
Authors’ contributions
IGV and JMK conceived the study, with substantial contributions from AM,
SS and RMD. Field data were collected under the supervision of IGV. AM, SS,
JMK, and IGV analyzed and interpreted the data and wrote the manuscript.
All authors read and approved the final version of the manuscript.
Competing interests
The authors declare that they have no competing interests.
Manirakiza et al. BMC Public Health 2011, 11:327
http://www.biomedcentral.com/1471-2458/11/327
Page 6 of 7Received: 5 November 2010 Accepted: 17 May 2011
Published: 17 May 2011
References
1. WHO: Measles vaccines: WHO position paper. Weekly Epidemiol Rec 2009,
35(84):349-360.
2. HDR: Country Profiles and International Human Development Indicators.
2010 [http://hdrstats.undp.org/en/countries/profiles/CAF.html].
3. United., Nations: Millennium Development Goals Indicators. 2010 [http://
mdgs.un.org/unsd/mdg/Default.aspx].
4. Dabis F, Waldman RJ, Mann GF, Commenges D, Madzou G, Jones TS: Loss
of maternal measles antibody during infancy in an African city. IEA;
1989:18:264.
5. Gendrel D, Engohan E, Gendrel C, Makanga MT, Garin D, Moussavou A,
Xueref C, Ajjan N: Disparition des anticorps antirougeoleux d’origine
maternelle chez le nourrisson gabonais = Disappearing of antimeasles
antibodies of maternal origine in the gabonese infant. SOPEMI;
1987:34:29-32.
6. Halsey NA, Boulos R, Mode F, Andre J, Bowman L, Yaeger RG, Toureau S,
Rohde J, Boulos C: Response to measles vaccine in Haitian infants 6 to
12 months old. Massachusetts Medical Society; 1985:313:544-549.
7. Hartter HK, Oyedele OI, Dietz K, Kreis S, Hoffman JP, Muller CP: Placental
transfer and decay of maternally acquired antimeasles antibodies in
Nigerian children. 2000, 19:635.
8. Sultana R, Rahman MM, Hassan Z, Hassan MS: Prevalence of IgG antibody
against measles, mumps and rubella in Bangladeshi children: a pilot
study to evaluate the need for integrated vaccination strategy. Wiley
Online Library; 2006:64:684-689.
9. Tapia MD, Sow SO, Medina-Moreno S, Lim Y, Pasetti MF, Kotloff K,
Levine MM: A serosurvey to identify the window of vulnerability to wild-
type measles among infants in rural Mali. ASTMH; 2005:73:26.
10. WHO: WHO UNICEF Joint Reporting Form data; WHO UNICEF Best
Estimates. 2010 [http://www.who.int/immunization_monitoring/data/
data_subject/en/index.html].
11. Okoko BJ, Wesuperuma LH, Ota MO, Banya WA, Pinder M, Gomez FS,
Osinusi K, Hart AC: Influence of placental malaria infection and maternal
hypergammaglobulinaemia on materno-foetal transfer of measles and
tetanus antibodies in a rural west African population. J Health Popul Nutr
2001, 19(2):59-65.
12. MICSS-RCA: Enquête à indicateurs multiples couplée avec la sérologie
VIH et anémie en RCA, 2006. 2010 [http://www.unicef.org/infobycountry/
car_statistics.html].
13. UNICEF: Global Acute Malnutrition. 2010 [http://www.unicef.org/
infobycountry/media_50744.html].
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2458/11/327/prepub
doi:10.1186/1471-2458-11-327
Cite this article as: Manirakiza et al.: Seroprevalence of measles and
natural rubella antibodies among children in Bangui, Central African
Republic. BMC Public Health 2011 11:327.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Manirakiza et al. BMC Public Health 2011, 11:327
http://www.biomedcentral.com/1471-2458/11/327
Page 7 of 7